Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (November 2020)

43 slides from Windtree Therapeutics's investor presentation, Nov 16, 2020

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics Company Overview November 15, 2020 WINDTREE THERAPEUTICS

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company

  3. Slide 3: Windtree company highlights

    @ RRQ QR 2 WINDTREE @ ee Tr) WINDTREE THERAPEUTICS" Biopharmaceutical / device company located in Pennsylvania with research operations in Milan and Taipei. NASDAQ: WINT Multiple clinical assets and a pipeline focused on important acute cardiovascular and acute pulmonary needs and markets Currently

  4. Slide 4: Windtree Therapeutics

    Windtree Therapeutics Windtree Therapeuticsis a clinical-stage biopharmaceutical and medical device company with multiple advanced clinical programs spanning cardiovascularand respiratory disease states Lead Products Pre- | Phase! | Phase ll | Phase Ill |Next Milestone FDA Fast Track |staroxime * In

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones = Four clinical programs focused on significant markets with unmet needs * Multiple clinical and business milestones which may have the potential to be catalysts 2020 2021 a2 a3 a4 an a2 a3 a4 Istaroxime Early Cardiogenic Shock Study Ponte Data, £092 im

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism, SERCA2a Activator for the Treatment of Acute Heart Failure and Early Cardiogenic Shock

  7. Slide 7: Heart Failure — A Large Market with Significant Unmet Need

    Heart Failure — A Large Market with Significant Unmet Need The prevalence of heart failure is high and increasing (as is mortality) > 6MU.S., 18-20M worldwide patients > #1 cause of U.S. hospitalization in patients > 65 years old; + >1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) >

  8. Slide 8: Acute Heart Failure - Significant Healthcare Issue

    Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need * There has not been meaningful new pharmacologic advancements in acute heart failure for decades * Current approaches to acutely improve cardiac function are associated with unwanted effects: * Patients with low

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart. ? stimulation of SERCA2a activity enhances calcium reuptake resulting in improvement of the diastolic relaxation and subsequent contraction cycle Inhibiti

  10. Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary

    Istaroxime AHF Phase 2a & 2b Studies — Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients hy n=120 Dosing= 6 hour ADHF Patients 0.5, 1, 1.5ug/kg/min Infusion 22 (dyspnes plus need for IV furesemide > 40mg) Phase Phase n=120 Dosing= 24 hour 2b ADHF Patients 1.0, 1.5

  11. Slide 11: Primary Endpoint — Significant Changes in E/e' Ratio and Stroke Volume

    Primary Endpoint — Significant Changes in E/e' Ratio and Stroke Volume istaroxime 0.5 pig/kg/min vs. placebo 10 00 a0 20 g30 40 0 60 Infusion period = a sis * prvalue = 0.029 Sasine — Ghours Shows AB hous == Picebo-Conet pe isrcxineds velle/min istaroxime 1.0 ug/kg/min vs. placebo Infusion period *

  12. Slide 12: Systolic Blood Pressure Maintained or Increased During Treatment

    Systolic Blood Pressure Maintained or Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 ug/kg/min vs. placebo PPE SES =-9- Poceto- Cohort ee sarorined uelkg/min istaroxime 1.0 ug/kg/min vs. placebo + Tarusonperos 1 00s 5 __T pwvalue=0.011, ** p-values! GFR z = § z 10 20

  13. Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 1g/kg/min vs. placebo Istaroxime 1.0 1g/kg/min vs. placebo —————— 93 i é $ gofusion period a 6. Ot srssesreain : 2 iaiauunanun 2 Wes 45 oe Heart Bd G Rate “9 Infusion period 2 * pvalue= 0.014 a5 re es Pro re POSES eas =-2- Pac

  14. Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically significant arrhythmias Clinically significant arrhythmias ROK 05% 105% 105% 25.0% 100% 200% 200% on nox aa 150% ioox am i: 2a sist 20% sox ax cox Besine Bc seine at Giisteccoai paceamitliotoen, farmca-encris "-wtsuteis le ms Ventr

  15. Slide 15: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Create a strong phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 75 centers globally (estimates) Leverage characteristics in a target population whose needs match the un

  16. Slide 16: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output No satisfactory pharmacologic

  17. Slide 17: Istaroxime SBP Change from Baseline

    Istaroxime SBP Change from Baseline to 6 or 24 Hours from the Phase 2a and 2b Dose Groups Istaroxime has the pote! to improve blood pressure and organ perfusion in patients with AHF 20.0 Fy 18.0 — 16.0 iw 14.0 8 #120 2 B® 10.0 § 80 & § 6.0 8 = 40 a 8 2.0 0.0 2a Study 2b stugy | 2a Study 2b study 2a

  18. Slide 18: Istaroxime — Early Cardiogenic Shock in Severe AHF Study

    Istaroxime — Early Cardiogenic Shock in Severe AHF Study Goal: + Improve SBP with acceptable safety profile * Increased systolic and diastolic cardiac function without increasing heart rate, risk for arrythmias or myocardial oxygen demand + Support a breakthrough therapy regulatory application Ongoi

  19. Slide 19: Pre-Clinical Programs

    Pre-Clinical Programs Novel Oral SERCA2a Activators for HF + Acute Pulmonary Platform The Companyalso has early exploratory research programs to identify potential product candidates including: Cardiovascular Selective SERCA2a Dual Mechanism Compounds Activators for Heart Failure * Oral &iv. therapi

  20. Slide 20: COVID-19 Lung Injury Treatment

    COVID-19 E: Lung Injury Treatment Synthetic KL4 Surfactant for the Treatment of Lung Injury in COVID-19 Patients

  21. Slide 21: COVID-19 and ARDS Have A Significant Negative Impact

    COVID-19 and ARDS Have A Significant Negative Impact On Surfactant Related Lung Function Uses anglostin- ACE2is a surface molecule on Damaged Type 2 cells Increased likelihood of converting enzyme 2 alveolar Type 2 calls of lungs, results in impaired mechanical ventilation (ACE2) for entry into the

  22. Slide 22: KL4 Surfactant Significantly Reduced Mortality in Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N11 Study — With and Without Anti-Viral Agent "= Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 surfactant t

  23. Slide 23: Surfactant Administration In Severe COVID-19 Lung Injury

    Surfactant Administration In Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits = We believe our synthetic KL4 surfactant may have the potential to mitigate surfactant deficiency and resist the a widespread surfactant destruction that can occur asa | result of COVID-19 =

  24. Slide 24: Lucinactant (KL4 Surfactant) For The Treatment of COVID-19

    Lucinactant (KL4 Surfactant) For The Treatment of COVID-19 Initial phase 2 study is to demonstrate changes in physiological parameters in COVID-19 associated lung injury and ARDS &_ * Upto 20 patients from 4-5 US sites ==> —__ Ied by investigators at Brigham & Women’s and Duke Medical Center * Dosin

  25. Slide 25: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19 — Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic De nonstrated Utility

  26. Slide 26: AEROSURF®

    AEROSURF® Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System for the Treatment of RDS

  27. Slide 27: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and gas exchange = Physicians must choose between invasive surfactant deliv

  28. Slide 28: AEROSURF® - Potential to Impact the Clinical Course of RDS

    sez @ Zz @ AEROSURF® - Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Long-Term Respiratory Outcomes Study results across each Parameters of these important parameters show evidence of a potential impact on the cli

  29. Slide 29: AEROSURF® Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach (1 Execute a small (n=~80 - 90) Bridging Study to transition to EOP2 / Phase 3: * Demonstrate the new ADS works and supplement phase 2 data * Optimize dosing with more drug and shorter repeat intervals v Transit

  30. Slide 30: Summary

    Summary

  31. Slide 31: Financial Summary & Capitalization as of Sept. 30, 2020

    Financial Summary & Capitalization as of Sept. 30, 2020 = Cash & Equivalents of ~$22.4 million = Bank Debt: ~$2.4M credit facility due in March 2022 Securities Common Equivalents Common Stock 16,921,482 Options (WAEP $15.76) 1,906,878 Warrants (WAEP $16.40) 7,896,150 Fully Diluted Equivalents 26,724

  32. Slide 32: Strategy for Value Generation

    Strategy for Value Generation SR we WINDTREE THERAPEUTICS. GS Strong Clinical Execution to Deliver Milestones: Execute well our several important, late-stage clinical programs for news flow and achievement of milestones that may be catalysts for growth Of Transactions: * Secure focused BD transactio

  33. Slide 33: Windtree Therapeutics

    Windtree Therapeutics “Striving to deliver Hope for a Lifetime!” we GS winDTtREE

  34. Slide 34: Appendix

    Appendix Se wINDTREE we" .

  35. Slide 35: In-Hospital Mortality, %

    In-Hospital Mortality, % Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF Patients and Their Outcomes In-Hospital Mortality Rates by Admission Systolic Blood Pressure Deciles (n = 48,567) I [50-104 105-114] 115-123 124-191 192-199 140-147 148-156 167-168 169-188

  36. Slide 36: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: ° LVEF < 35% © SBP 90-150 mmHg =

  37. Slide 37: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events istaroxime 0.5 istaroxime 1.0 Pooled placebo (n=39) Alladverse events Adverse events leat discontinuation gto Serious adverse events Cardiac death enic shock Cardiac failure Renal embolism Transient ischemic attack Hyperventilation Hypotension Adverse Drug Reaction

  38. Slide 38: References Supporting Utilization of KL4 Surfactant

    References Supporting Utilization of KL, Surfactant for the Treatment of Lung Injury Hoffmann, ML, H. Kleine Weber, etal, (2020). "The novel coronavirus 2019 (2019-nCoV) uses the SARS-corcnavirus receptor ACE2 andthe cellular protease TMPRSS2 for entry into target cells10.1101/2020.01.31.929042." bi

  39. Slide 39: Surfactant in ARDS References

    Surfactant in ARDS References 1. Gregory TI, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore W4, et al. Bovine surfactant therapy for patients with acute respiratory distresssyndrome.Am J Respir Crit Care Med. 1997;155:1309-1315. 2. Wiedemann H, Baughman R, de BoisblancE,et al.,A multi centered

  40. Slide 40: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Phe: h ‘ Initial treatment options include invasive and noninvasive meth

  41. Slide 41: Windtree Technology Platform - AEROSURF®

    Windtree Technology Platform - AEROSURF® Proprietary Synthetic KL4 Surfactant + Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) ability to aerosolize KLa surfactant for RDS approved by the FDA Lyo

  42. Slide 42: Transformative Potential of AEROSURF®

    Transformative Potential of AEROSURF® RISKS Surfactant Therapy respiration Surfactant therapy delivers near-immediate clinical improvement Reversing surfactant deficieney.has /a profound positive impact on\ BPD Infection, ventilator-induced pneumonia ncPAP Respiratory Support “Avoids exposure to the

  43. Slide 43: Business Development Focus

    Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Miditernh Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Ou

Windtree Therapeutics — Investor Presentation (November 2020) on 6ix